TWI907427B - 經工程化之t細胞受體及其使用方法 - Google Patents

經工程化之t細胞受體及其使用方法

Info

Publication number
TWI907427B
TWI907427B TW110117938A TW110117938A TWI907427B TW I907427 B TWI907427 B TW I907427B TW 110117938 A TW110117938 A TW 110117938A TW 110117938 A TW110117938 A TW 110117938A TW I907427 B TWI907427 B TW I907427B
Authority
TW
Taiwan
Prior art keywords
tcr
cells
seq
amino acid
cancer
Prior art date
Application number
TW110117938A
Other languages
English (en)
Chinese (zh)
Other versions
TW202146438A (zh
Inventor
嘉誠 余
潘科
Original Assignee
美國德州系統大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國德州系統大學評議委員會 filed Critical 美國德州系統大學評議委員會
Publication of TW202146438A publication Critical patent/TW202146438A/zh
Application granted granted Critical
Publication of TWI907427B publication Critical patent/TWI907427B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW110117938A 2020-05-18 2021-05-18 經工程化之t細胞受體及其使用方法 TWI907427B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026445P 2020-05-18 2020-05-18
US63/026,445 2020-05-18

Publications (2)

Publication Number Publication Date
TW202146438A TW202146438A (zh) 2021-12-16
TWI907427B true TWI907427B (zh) 2025-12-11

Family

ID=78708026

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110117938A TWI907427B (zh) 2020-05-18 2021-05-18 經工程化之t細胞受體及其使用方法

Country Status (8)

Country Link
US (1) US20230190812A1 (enExample)
EP (1) EP4153618A4 (enExample)
JP (1) JP7785696B2 (enExample)
CN (1) CN116322715A (enExample)
AU (1) AU2021276264A1 (enExample)
CA (1) CA3183663A1 (enExample)
TW (1) TWI907427B (enExample)
WO (1) WO2021236548A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
CN114149978B (zh) * 2022-02-09 2022-04-26 深圳博雅感知药业有限公司 制备car-t细胞的方法
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN120924527B (zh) * 2025-10-16 2026-02-06 内蒙古科为博生物科技有限公司 一种内切葡聚糖酶突变体eg06、其编码基因及其产品与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002086A1 (ja) * 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2017175006A1 (en) * 2016-04-08 2017-10-12 Immunocore Limited T cell receptors
US20190292520A1 (en) * 2018-03-21 2019-09-26 Immatics US, Inc. Method of enhancing persistence of adoptively infused t cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP3572510B1 (en) * 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
AU2018395397A1 (en) * 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061876A1 (en) * 2017-12-29 2021-03-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
KR20200119840A (ko) * 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002086A1 (ja) * 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
WO2017175006A1 (en) * 2016-04-08 2017-10-12 Immunocore Limited T cell receptors
US20190292520A1 (en) * 2018-03-21 2019-09-26 Immatics US, Inc. Method of enhancing persistence of adoptively infused t cells

Also Published As

Publication number Publication date
WO2021236548A1 (en) 2021-11-25
EP4153618A1 (en) 2023-03-29
JP2023528255A (ja) 2023-07-04
TW202146438A (zh) 2021-12-16
US20230190812A1 (en) 2023-06-22
CA3183663A1 (en) 2021-11-25
AU2021276264A1 (en) 2022-12-22
EP4153618A4 (en) 2024-06-26
JP7785696B2 (ja) 2025-12-15
CN116322715A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
EP4423116A1 (en) Methods and compositions for treating glioblastoma
TWI893070B (zh) 經工程化之t細胞受體及使用方法
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20260125448A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
HK40113193A (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
HK40092477A (en) Engineered t cell receptors and methods of use
CN117425482A (zh) 靶向egfr抗原的经改造t细胞受体和使用方法
CN118302176A (zh) 靶向mage-a4抗原的肽和经改造t细胞受体及使用方法
EP4430197A2 (en) Engineered immune cells and methods for use